The ILA encompasses the legal framework CME Group uses to license the consumption of market data and must be completed to gain access to CME Direct.
Yes, both agreements are required to gain access to CME Direct. The EULA is the software agreement, whereas the ILA is specific to the consumption of market data.
Any authorized representative within your organization can sign the Agreements.
As a matter of policy, all CME Direct firms are required to complete an ILA.
No, the license to use market data on CME Direct is only available by signing the ILA.
The Agreement goes into effect on the effective date stated on the Agreement after both parties have signed.
The term is the period from the effective date until the termination of the Agreement. Either party may terminate the agreement on 30 days’ notice.
Fees will be charged per standard market data policy, on a per Device, per Exchange basis.
*Fee schedule above is effective 1 April 2021. For more information regarding fees, visit our Real-Time Professional Fee page.
CME Group defines Device as any display unit (fixed or portable), piece of software or method, which may access, receive, process or display the Information, whether in whole or part, through the Service. CME reserves the sole right to determine what constitutes a Device.
No, CME Direct Mobile devices qualify as a waived device.
No, only real-time professional data fees are available on CME Direct.
Users can qualify for a market data fee waiver by meeting a volume threshold on the CME Direct platform. The volume threshold is set to an average daily volume (ADV) of one per calendar quarter. The waiver applies only to the four CME Group exchanges, CME, CBOT, NYMEX and COMEX. Standard fees apply for Dubai Mercantile Exchange market data (DME).
Yes, the ADV threshold must be met for each exchange permissioned.
Yes, volume from both CME Globex transactions and CME ClearPort deals entered via CME Direct will count towards ADV for the quarter.
Yes, any named party on a CME ClearPort deal entered via CME Direct will benefit. This includes named brokers and traders who are not the submitters of the transaction.
Only the user who enters the futures/options trade via CME Direct will benefit.
Fees and waivers will be applied monthly based on the previous quarter’s usage evaluation. The first granted Exchanges automatically qualify for a waiver in the first calendar quarter they are enabled and the following two quarters. In the third quarter after access to market data on the first Exchange is permissioned, quarterly evaluation begins.
During an evaluation quarter, trading activity is assessed on each Exchange independently. Users who achieve an ADV greater than or equal to one qualify for the waiver. The qualification applies to the bill for each month in the next calendar quarter.
No, the newly added market data will qualify as waived for the balance of the quarter it is granted and then go into evaluation as referenced above.
For example, a user permissioned for CBOT market data in January will be charged for the first time in October based on their Q3 ADV.
Firm Administrators can complete all administrative tasks without the need for market data permissioned, including cancelling and holding company CME Globex orders. If an Administrator wants market data permissioned, the policy will waive fees for a single admin when at least one trading user at the firm has met the ADV threshold on a per Exchange basis.
No, only trades submitted through CME Direct are eligible.
Yes, CME Group will bill customer firms directly for real-time market data access on CME Direct.
No, firms will be invoiced by CME Group and are required to pay CME Group directly.
CME Direct can be used for deal entry to CME ClearPort without market data being permissioned. Market permission sets under the over-the-counter (OTC) venues are not billable.
Yes, if you are an enabled CME Direct user and permissioned for market data at any point during the month, you will be charged.
Firm Administrators can adjust market data permissions from the User Admin view in CME Direct. Additionally, users can be disabled from the User Admin view.
For general inquiries:
For market data licensing:
U.S.: +1 312 634 8395
Europe: +44 20 3379 3754
Asia: +65 6593 5505
For onboarding and entitlements:
Enterprise Application & System Entitlements (EASE)
U.S.: +1 312 456 1560
Europe: +44 203 379 3802
Asia: +65 6593 5536